Adial Pharmaceuticals (NASDAQ:ADIL) Major Shareholder Acquires $28,047.87 in Stock

Posted by Brian Himes on Jul 16th, 2026

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) major shareholder Coastlands Capital Lp bought 10,053 shares of the stock in a transaction on Thursday, July 9th. The shares were acquired at an average cost of $2.79 per share, for a total transaction of $28,047.87. Following the acquisition, the insider directly owned 383,375 shares in the company, valued at approximately $1,069,616.25. This trade represents a 2.69% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Coastlands Capital Lp also recently made the following trade(s):

On Friday, July 10th, Coastlands Capital Lp bought 1,700 shares of Adial Pharmaceuticals stock. The stock was bought at an average price of $2.70 per share, with a total value of $4,590.00.
On Monday, June 29th, Coastlands Capital Lp bought 25,000 shares of Adial Pharmaceuticals stock. The shares were bought at an average cost of $2.60 per share, with a total value of $65,000.00.

Adial Pharmaceuticals Stock Up 2.6%

Shares of ADIL opened at $2.72 on Thursday. Adial Pharmaceuticals, Inc. has a twelve month low of $1.31 and a twelve month high of $18.90. The stock has a market cap of $5.83 million, a PE ratio of -0.34 and a beta of 1.43. The business’s 50-day moving average price is $2.37 and its 200-day moving average price is $2.88.

Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last issued its quarterly earnings data on Friday, May 8th. The company reported ($1.48) EPS for the quarter, beating the consensus estimate of ($2.73) by $1.25.

Analysts Set New Price Targets

ADIL has been the subject of several research analyst reports. Loop Capital set a $6.00 price objective on Adial Pharmaceuticals in a research note on Monday, June 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research note on Monday, April 20th. Needham & Company LLC downgraded Adial Pharmaceuticals to a “buy” rating in a research report on Monday, June 15th. Finally, Brookline Capital Markets lowered Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $17.17.

Read Our Latest Stock Report on ADIL

Institutional Trading of Adial Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Armistice Capital LLC acquired a new stake in Adial Pharmaceuticals during the fourth quarter valued at approximately $562,000. Citadel Advisors LLC bought a new stake in Adial Pharmaceuticals in the third quarter valued at $51,000. Finally, Jane Street Group LLC raised its stake in Adial Pharmaceuticals by 887.3% during the fourth quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock worth $27,000 after acquiring an additional 109,500 shares in the last quarter. Institutional investors own 16.41% of the company’s stock.

About Adial Pharmaceuticals

(Get Free Report)

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.